Skip to main content
ST PHARM CO., LTD. logo

ST PHARM CO., LTD. — Investor Relations & Filings

Ticker · 237690 ISIN · KR7237690003 KO Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2026-03-26 Declaration of Voting R…
Country KR South Korea
Listing KO 237690

About ST PHARM CO., LTD.

https://www.stpharm.co.kr/en

ST PHARM CO., LTD. is a global Contract Development and Manufacturing Organization (CDMO) specializing in Active Pharmaceutical Ingredients (APIs). The company provides technology-driven manufacturing services for gene therapies, with core expertise in oligonucleotides and various forms of RNA (xRNA), including messenger RNA (mRNA). In addition to nucleic acid-based medicines, ST Pharm offers custom manufacturing for small molecule APIs. The company's services operate under cGMP (current Good Manufacturing Practice) standards, providing comprehensive solutions that support the entire drug development lifecycle, from research and development to commercial-scale production for its global pharmaceutical partners.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled "정기주주총회결과" (Regular Shareholders’ Meeting Results) and provides detailed voting outcomes for each agenda item at the Annual General Meeting (AGM), including approval of financial statements, dividend resolutions, director elections, and vote percentages. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes at any general meeting.
2026-03-26 Korean
주식매수선택권부여에관한신고
Regulatory Filings Classification · 60% confidence The document is a Korean regulatory disclosure (“주식매수선택권 부여에 관한 신고”) filed with the Financial Services Commission and Korea Exchange, detailing the grant of stock options by ST Pharm to directors, officers, and employees. It is not an earnings release, annual report, management change notice, or any other category with a specific match, nor is it a US proxy/DEF 14A. Since there is no dedicated “stock option grant” category in the taxonomy, the filing defaults to the general “Regulatory Filings” category (RNS).
2026-03-26 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 95% confidence The document is a formal notification (신고) to the Financial Services Commission/Korea Exchange regarding the appointment, dismissal, and mid-term resignation of outside directors (사외이사). It details changes in board composition, names, dates, and positions of directors. This corresponds to an announcement of changes in the company’s board of directors or senior management, matching the Board/Management Information category.
2026-03-26 Korean
감사보고서제출
Audit Report / Information Classification · 99% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It provides the audit opinion (which is 'unqualified' or '적정'), financial highlights (assets, liabilities, equity, revenue, profit), and confirms the receipt of the audit report from the external auditor (Samjong KPMG). While it contains financial data, it is a standard regulatory disclosure announcement regarding the filing of the audit report, not the full annual report itself. Therefore, it falls under the category of Audit Report / Information. FY 2025
2026-03-18 Korean
사업보고서 (2025.12)
Annual Report Classification · 100% confidence The document is titled '사업보고서' (Business Report) for the 18th fiscal period (2025), submitted to the Financial Services Commission and Korea Exchange. It contains comprehensive information including company overview, history, capital changes, and detailed business descriptions. This matches the definition of an Annual Report (10-K) in the provided schema, which covers yearly company activity and financial performance. FY 2025
2026-03-18 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 95% confidence The document is a formal regulatory disclosure from ST Pharm regarding a 'Single Sales/Supply Contract' (단일판매ㆍ공급계약체결). It details the contract value, counterparty, duration, and terms. In the context of Korean regulatory filings (DART), this is a standard material event disclosure. Since it does not fit into specific categories like M&A, dividends, or share issues, and is a formal regulatory announcement of a business contract, it is classified as a Regulatory Filing (RNS).
2026-03-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.